Top Industry Leaders in the Viral Vector Manufacturing Market
Latest Viral Vector Manufacturing Companies Updates:
Lonza: Expanded its viral vector manufacturing capacity with a new facility in Switzerland, offering commercial-scale production for diverse gene therapy applications.
Sartorius: Acquired Cell & Gene Therapy Platform from Sartorius Stedim Biotech, gaining expertise and technologies for large-scale viral vector production using single-use bioreactors.
Catalent: Introduced its Opti™Viral platform, a modular and scalable solution for optimizing viral vector design and manufacturing processes, aiming to accelerate development and reduce costs.
Boehringer Ingelheim: Partnered with Viral Vector Producer to manufacture its innovative gene therapy candidate for treating beta-thalassemia, demonstrating commitment to advancing the field.
Charles River: Partnered with Rznomics, a South Korean biopharma, to develop and manufacture viral vectors for a gene therapy targeting liver cancer, highlighting collaborative efforts in Asia.
The Alliance for Regenerative Medicine (ARM): Collaborated with industry leaders and regulatory bodies to advocate for streamlined regulations and promote responsible development of viral vector-based therapies.
List of Viral Vector Manufacturing Key companies in the market:
-
Catalent Inc.
-
Avid Bioservices Inc.
-
AGC Biologics
-
Thermofisher Scientific Inc.
-
Cognate Bioservices
-
FinVector
-
Merck KgaA
-
Waisman Biomanufacturing
-
GenScript Biotech Corporation
